Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Rowe JM (2009) Optimal induction and post-remission therapy for AML in first remission. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program:396-405. doi:10.1182/asheducation-2009.1.396

  2. 2.

    Kaspers GJ, Zwaan CM (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92(11):1519–1532

    Article  PubMed  Google Scholar 

  3. 3.

    Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122(1):53–60

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Cohen SS (1976) The lethality of aranucleotides. Med Biol 54(5):299–326

    CAS  PubMed  Google Scholar 

  5. 5.

    Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P (2012) Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3):269–282. doi:10.2217/pgs.11.149

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Braess J, Pfortner J, Kern W, Hiddemann W, Schleyer E (1999) Cytidine deaminase—the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 78(11):514–520

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Ciccolini J, Dahan L, Andre N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 28(1):160–165

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, Ciccolini J (2007) Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 17(10):841–844

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM (2009) Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 144(3):388–394. doi:10.1111/j.1365-2141.2008.07461.x

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. 10.

    Forghieri F, Luppi M, Morselli M, Potenza L (2007) Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica 92(9):e85–90

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64(2):728–735

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the Department of Biotechnology, India for the financial assistance given to the principal investigator PB (Grant no: BT/01/COE/08/03). AA and SK are recipients of fellowship from University Grants Commission (UGC), India. VM is supported by the Wellcome-DBT senior fellowship program.

Conflict of interest

The authors have no conflicts of interest to disclose.

Author contributions

AA performed the research, analyzed the data, and wrote the paper. AJD performed the clinical data accrual, analyzed the data, and wrote the paper. SV performed the research. SK performed the research. PB was the principal investigator, designed the study, performed the research, analyzed the data, and wrote the paper. VM performed the clinical data accrual, analyzed the data, and wrote the paper.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vikram Mathews.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abraham, A., Devasia, A.J., Varatharajan, S. et al. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann Hematol 94, 883–885 (2015). https://doi.org/10.1007/s00277-014-2254-2

Download citation

Keywords

  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Patient
  • Invasive Pulmonary Aspergillosis
  • Uracil Arabinoside
  • Remission Induction Regimen